Intellia Therapeutics is a leading clinical-stage company developing potentially curative gene editing treatments for people living with severe and life-threatening diseases. Uses CRISPR/Cas9 system to harness genome-editing technology for human therapeutic use. It has partnerships with Novartis and Regeneron.

Intellia is committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.